Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

• Published in: Journal of comparative effectiveness research Vol. 12; no. 6; p. e220188
• Main Authors: Watt, Maureen, Malmenäs, Mia, Romanus, Dorothy, Haeussler, Katrin
• Format: Journal Article
• Language: English
• Published: England Becaris Publishing Ltd 01.06.2023; Becaris Publishing Limited
• Subjects: Angioedemas, Hereditary - drug therapy; Angioedemas, Hereditary - prevention & control; Antibodies, Monoclonal, Humanized - therapeutic use; berotralstat; comparative effectiveness; hereditary angioedema; Humans; indirect treatment comparison; lanadelumab; Network Meta-Analysis; prophylaxis; comparative effectiveness; indirect treatment comparison; hereditary angioedema; berotralstat; prophylaxis; lanadelumab
• ISSN: 2042-6305; 2042-6313
• DOI: 10.57264/cer-2022-0188

With no head-to-head studies comparing the effectiveness of lanadelumab and berotralstat for prevention of hereditary angioedema (HAE) attacks, this network meta-analysis (NMA) aimed to indirectly compare the effectiveness of these treatments. The NMA, using the published data from Phase III trials, was performed using a frequentist weighted regression-based approach following Rücker Efficacy outcomes of interest were HAE attack rate per 28 days and ≥90% reduction in monthly HAE attacks. In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.